Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QY211
- Development stage
- Phase 1
- Lead developer
- E-nitiate
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
QY211 is a small molecule drug developed by E-nitiate Biopharmaceuticals for the treatment of inflammatory skin diseases, primarily atopic dermatitis, psoriasis, and vitiligo. It acts as a dual inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), blocking the JAK kinase structural domain and inhibiting the JAK-STAT signaling pathway. This mechanism reduces inflammatory cytokine activity implicated in these dermatological conditions. The drug is being evaluated as a topical gel formulation in clinical trials for mild to moderate atopic dermatitis, with additional development for other skin disorders[1][2][3][4].
- Other names
- QY211QY-211QY 211
02
Targets
JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on QY211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QY211.